Table 2 |
|||||
|
Clinical characteristics of patients at baseline and after 24 and 48 weeks of adalimumab treatment |
|||||
| Variable |
Week 0 |
Week 24 |
P |
Week 48 |
P |
|
|
|||||
| DAS 28 |
5.4 ± 1.3 |
3.6 ± 1.2 |
<0.01 |
2.7 ± 0.9 |
<0.01 |
| Tender joint count |
12.4 ± 4.7 |
5.1 ± 3.5 |
<0.01 |
4.9 ± 3.5 |
<0.01 |
| Swollen joint count |
10.4 ± 3.8 |
3.2 ± 3.4 |
<0.01 |
3.12 ± 3.4 |
<0.01 |
| ESR (mm/h) |
35 ± 17 |
26 ± 16 |
<0.01 |
24 ± 15 |
<0.01 |
| CRP (mg/dl) |
42 ± 22.7 |
21 ± 15.2 |
<0.01 |
15 ± 14.8 |
<0.01 |
| Anti-CCP (AU)a |
116.9 ± 43.6 |
100.5 ± 46.5 |
<0.01 |
78.5 ± 43.9 |
<0.01 |
| RF (IU) |
121.7 ± 120.6 |
81 ± 90 |
<0.01 |
70.2 ± 82.7 |
<0.01 |
|
|
|||||
|
aOnly anti-CCP positive patients at baseline (46 of 57) were included in the evaluation. Results are mean values ± SD. AU, arbitrary units; CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS 28 = Disease Activity Score; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor. |
|||||
|
Atzeni et al. Arthritis Research & Therapy 2006 8:R3 doi:10.1186/ar1851 |
|||||
